Company news
Chiome Bioscience Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026
August 13, 2026
Announcement of target-specific research and option agreement with Heidelberg Pharma
July 13, 2022
Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
July 11, 2022
First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
July 4, 2022
Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
June 13, 2022
Submission of the application for a Phase I study of CBA-1535
February 16, 2022
License agreement for a diagnostic kit with Fujirebio, Inc.
February 15, 2022
Supplementary Information for Financial Results FY12/21
February 14, 2022
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
February 14, 2022
Move to the second half part of Phase 1 clinical trial of first-in-class CBA-1205
December 24, 2021
Supplement Documents for Financial Results Q3 FY12/21
November 12, 2021
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2021
November 12, 2021
Supplement Documents for Financial Results Q2 FY12/21
August 13, 2021
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2021
August 13, 2021
Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody
May 14, 2021
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2021
May 14, 2021
Supplement Documents for Financial Results Q1 FY12/21
May 14, 2021
Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development
May 14, 2021
Supplement Documents for Financial Results Q2 FY12/20
August 11, 2020
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2020
August 11, 2020